Clinical Trials Logo
  1. Home
  2. Hodgkin Lymphoma, Adult
  3. NCT03155425

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Hodgkin Lymphoma, Adult Clinical Trial

Official title:
An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma

Clinical Trial Summary

This is an open-label, multicenter, non-randomized, phase 2 trial to evaluate efficacy and safety of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma. The primary objective is to assess ORR of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma.

Clinical Trial Description

The primary objective of this phase 2 study is to assess objective response rate of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma. The secondary objective is to observe the duration of response, progression free survival, time to response, overall survival and safety of SHR-1210 in relapsed or refractory classic Hodgkin's lymphoma. Pharmacokinetic index is also investigated in 12 patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03155425
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Completed
Phase Phase 2
Start date June 9, 2017
Completion date September 30, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04653649 - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. Phase 1/Phase 2
Recruiting NCT04636255 - Physical Capacity in Hodgkin Lymphoma Survivors N/A
Not yet recruiting NCT06421987 - Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Recruiting NCT05597761 - Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
Active, not recruiting NCT03535948 - Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
Recruiting NCT03260101 - Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Recruiting NCT04776265 - RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Recruiting NCT04378647 - BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant Phase 2
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Recruiting NCT05137886 - PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma Phase 2
Recruiting NCT05798897 - Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Phase 1
Completed NCT04292626 - Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose Phase 1
Active, not recruiting NCT04268706 - Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) Phase 2
Recruiting NCT04638790 - First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) Phase 3
Completed NCT01578967 - Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma N/A
No longer available NCT03914885 - Compassionate Use Re-Infusion of ATLCAR.CD30